Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis
Name
44319_2015_Article_BFEMBR201540107.pdf
Size
2.29 MB
Format
Adobe PDF
Checksum (MD5)
644919801c338f24164effe652bc1fba
Author(s)
Madsen, Chris D.
Pedersen, Jesper T.
Venning, Freja A.
Singh, Lukram B.
Moeendarbary, Emad
Charras, Guillaume
Cox, Thomas R.
Sahai, Erik
Erler, Janine T.
Date Issued
August 31, 2015
Journal
Embo Reports
Publisher
Nature Publishing Group UK
Citation
EMBO rep (2015)16: 1394 - 1408
Version
Final published version
Abstract
Cancer‐associated fibroblasts (CAFs) interact with tumour cells and promote growth and metastasis. Here, we show that CAF activation is reversible: chronic hypoxia deactivates CAFs, resulting in the loss of contractile force, reduced remodelling of the surrounding extracellular matrix and, ultimately, impaired CAF‐mediated cancer cell invasion. Hypoxia inhibits prolyl hydroxylase domain protein 2 (PHD2), leading to hypoxia‐inducible factor (HIF)‐1α stabilisation, reduced expression of αSMA and periostin, and reduced myosin II activity. Loss of PHD2 in CAFs phenocopies the effects of hypoxia, which can be prevented by simultaneous depletion of HIF‐1α. Treatment with the PHD inhibitor DMOG in an orthotopic breast cancer model significantly decreases spontaneous metastases to the lungs and liver, associated with decreased tumour stiffness and fibroblast activation. PHD2 depletion in CAFs co‐injected with tumour cells similarly prevents CAF‐induced metastasis to lungs and liver. Our data argue that reversion of CAFs towards a less active state is possible and could have important clinical implications.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.15252/embr.201540107
